GPP
Bridging the Gap in Generalized Pustular Psoriasis
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses insights gathered from GPP patients.
Search
46 Result(s)
GPP
Generalized pustular psoriasis (GPP): a rare, chronic, systemic disease
A rare, chronic, systemic autoinflammatory disease that can be life-threatening if left untreated.
GPP
The generalized pustular psoriasis (GPP) Forum 2023
An executive summary of the activities and key takeaways from the GPP Forum 2023
GPP
Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
GPP
Generalized pustular psoriasis: Unmet needs
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
December 13, 2022
EC grants conditional marketing authorization for spesolimab
September 02, 2022
First approval for SPEVIGO® to treat GPP flares
GPP
Generalized pustular psoriasis: The value of collaboration
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
GPP
GPP: Impact Beyond The Skin
An article on how the symptoms of generalized pustular psoriasis (GPP) are more than just physical, affecting both mental and emotional health
GPP
Spotlight on Generalized Pustular Psoriasis
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
GPP
Shining a Light on Generalized Pustular Psoriasis
On World Psoriasis Day, Professor Barker talks about increasing awareness of generalized pustular psoriasis in the dermatology community
GPP
EADV 2021: New frontiers in GPP
Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
Article
Live well with Generalized Pustular Psoriasis
Learn about why it is important to increase awareness of Generalized Pustular Psoriasis (GPP) and tips that people living with GPP have shared to live well with the disease.
Article
Unmet needs in Generalized Pustular Psoriasis (GPP)
Learn more about the unmet needs of people living with GPP and how multi-level support can be implemented to improve the lives patients.
January 30, 2023
Spesolimab meets key endpoint for GPP flare prevention
July 04, 2023
Spesolimab prevents GPP flares
October 14, 2022
CHMP recommends conditional approval for first GPP treatment
May 02, 2023
Breakthrough Designation granted in US and China
December 23, 2021
Spesolimab Phase II data
March 28, 2022
New spesolimab data show significant improvement in GPP flares
October 29, 2021
EMA validates spesolimab marketing authorization application in GPP
GPP
The Goals to Improve Living with GPP
An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis
December 15, 2021
U.S. FDA grants priority review for spesolimab in GPP
Article
Generalised Pustular Psoriasis (GPP) : a rare and chronic autoinflammatory skin disease
An infographic focused on generalised pustular psoriasis as a distinct, rare form of psoriasis
GPP
World Psoriasis Day (WPD)
Interview with the International Federation of Psoriasis Associations (IFPA)